press releases

The RTOG 3503 phase 2 pilot trial is the first consortium study to test treatment with Optune ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure™ (NASDAQ: NVCR) announced today that the first patient has been enrolled in the RTOG Foundation’s phase 2 pilot trial testing Optune together with bevacizumab for… Read More

More than 204 million Americans will have coverage of Optune as a treatment for newly diagnosed and/or recurrent glioblastoma ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that Health Care Service Corporation (HCSC) will cover Optune for members who have newly diagnosed glioblastoma (GBM) effective… Read More

More than 204 million Americans will have coverage of Optune as a treatment for newly diagnosed and/or recurrent glioblastoma ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that Health Care Service Corporation (HCSC) will cover Optune for members who have newly diagnosed glioblastoma (GBM) effective… Read More

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will participate in the JMP Securities 2017 Life Sciences Conference on June 21, 2017, in New York. Dr. Eilon Kirson, Novocure’s Chief Science Officer and Head of Research and Development, will speak on behalf of the company and address… Read More

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will participate in the JMP Securities 2017 Life Sciences Conference on June 21, 2017, in New York. Dr. Eilon Kirson, Novocure’s Chief Science Officer and Head of Research and Development, will speak on behalf of the company and address… Read More

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that United States Food and Drug Administration (FDA) has designated it’s Tumor Treating Fields (TTFields) delivery system as a Humanitarian Use Device (HUD) for the treatment of pleural mesothelioma. HUD designation covers devices that treat rare, orphan diseases or… Read More

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that United States Food and Drug Administration (FDA) has designated it’s Tumor Treating Fields (TTFields) delivery system as a Humanitarian Use Device (HUD) for the treatment of pleural mesothelioma. HUD designation covers devices that treat rare, orphan diseases or… Read More

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) today announced that Martin J. Madden, a longtime leader in the medical device industry, was elected to its Boards of Directors during Novocure’s 2017 annual general meeting of shareholders. In addition, Mr. Madden has been appointed to Novocure’s Audit and Nominating and Corporate… Read More

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) today announced that Martin J. Madden, a longtime leader in the medical device industry, was elected to its Boards of Directors during Novocure’s 2017 annual general meeting of shareholders. In addition, Mr. Madden has been appointed to Novocure’s Audit and Nominating and Corporate… Read More